Adverse events and costs among non-metastatic castration-resistant prostate cancer patients

CONCLUSION: There is significant HCRU and cost burden among nmCRPC patients treated with ARAs developing AEs, highlighting the need for treatments with improved tolerability. Additional studies are warranted to include recently approved agents.PMID:38174553 | DOI:10.1080/13696998.2023.2299179

Source: Journal of Medical Economics - January 4, 2024 Category: Health Management Authors: Sreevalsa Appukkuttan Jianying Yao Jamie Partridge Sheldon X Kong Jacqueline Parkin Stephen J Freedland Source Type: research